Archives of Pediatric Infectious Diseases

Published by: Kowsar

Contribution of gyrA and qnrA genes in Ciprofloxacin Resistant Ecsherichia coli Isolates from Patients with Urinary Tract Infections of Imam Khomeini Hospital of Tehran

Zahra Zahedi 1 , Mojdeh Hakemi Vala 2 , 3 , * and Fatemeh Bagheri Bejestani 1
Authors Information
1 Department of Microbiology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
2 Department of Microbiology, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Pediatric Infectious Diseases: October 2018, 6 (4); e62129
  • Published Online: August 6, 2018
  • Article Type: Research Article
  • Received: October 3, 2017
  • Revised: February 12, 2018
  • Accepted: February 17, 2018
  • DOI: 10.5812/pedinfect.62129

To Cite: Zahedi Z, Hakemi Vala M, Bagheri Bejestani F. Contribution of gyrA and qnrA genes in Ciprofloxacin Resistant Ecsherichia coli Isolates from Patients with Urinary Tract Infections of Imam Khomeini Hospital of Tehran, Arch Pediatr Infect Dis. 2018 ; 6(4):e62129. doi: 10.5812/pedinfect.62129.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Abdi S, Ranjbar R, Hakemi Vala M, Jonaidi N, Baghery Bejestany O, Baghery Bejestany F. Frequency of bla TEM, bla SHV, bla CTX-M, and qnrA among Escherichia coli isolated from urinary tract infection. Arch Clin Infect Dis. 2014;9(1). doi: 10.5812/archcid.18690.
  • 2. Kass EH. Asymptomatic infections of the urinary tract. J Urol. 2002;167(2):1016-20. doi: 10.1016/s0022-5347(02)80328-7.
  • 3. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Disease control priorities in developing countries. Washington (DC); 2006.
  • 4. Cheng G, Hao H, Dai M, Liu Z, Yuan Z. Antibacterial action of quinolones: from target to network. Eur J Med Chem. 2013;66:555-62. doi: 10.1016/j.ejmech.2013.01.057. [PubMed: 23528390].
  • 5. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat. 1999;2(1):38-55. doi: 10.1054/drup.1998.0068. [PubMed: 11504468].
  • 6. Gellert M, Mizuuchi K, O'Dea MH, Nash HA. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A. 1976;73(11):3872-6. [PubMed: 186775]. [PubMed Central: PMC431247].
  • 7. Kreuzer KN, Cozzarelli NR. Formation and resolution of DNA catenanes by DNA gyrase. Cell. 1980;20(1):245-54. [PubMed: 6248235].
  • 8. Han XY, Han FS, Segal J. Chromobacterium haemolyticum sp. nov., a strongly haemolytic species. Int J Syst Evol Microbiol. 2008;58(Pt 6):1398-403. doi: 10.1099/ijs.0.64681-0. [PubMed: 18523185].
  • 9. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother. 2003;47(10):3222-32. [PubMed: 14506034]. [PubMed Central: PMC201150].
  • 10. El-Sokkary MMA, Abdelmegeed ES. Antibacterial resistance pattern among Escherichia coli strains isolated from Mansoura hospitals in Egypt with a special reference to quinolones. Afr J Microbiol Res. 2015;9(9):662-70. doi: 10.5897/ajmr2014.7351.
  • 11. Oppegaard H, Sorum H. Cloning and nucleotide sequence of the DNA gyrase gyrA gene from the fish pathogen Aeromonas salmonicida. Antimicrob Agents Chemother. 1996;40(5):1126-33. [PubMed: 8723452]. [PubMed Central: PMC163277].
  • 12. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother. 2003;51(5):1109-17. doi: 10.1093/jac/dkg222. [PubMed: 12697644].
  • 13. Gruger T, Nitiss JL, Maxwell A, Zechiedrich EL, Heisig P, Seeber S, et al. A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II. Antimicrob Agents Chemother. 2004;48(12):4495-504. doi: 10.1128/AAC.48.12.4495-4504.2004. [PubMed: 15561817]. [PubMed Central: PMC529191].
  • 14. Jacoby GA, Walsh KE, Mills DM, Walker VJ, Oh H, Robicsek A, et al. qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother. 2006;50(4):1178-82. doi: 10.1128/AAC.50.4.1178-1182.2006. [PubMed: 16569827]. [PubMed Central: PMC1426915].
  • 15. Cavaco LM, Hasman H, Xia S, Aarestrup FM. qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. Antimicrob Agents Chemother. 2009;53(2):603-8. doi: 10.1128/AAC.00997-08. [PubMed: 19029321]. [PubMed Central: PMC2630628].
  • 16. Jacoby G, Cattoir V, Hooper D, Martinez-Martinez L, Nordmann P, Pascual A, et al. qnr Gene nomenclature. Antimicrob Agents Chemother. 2008;52(7):2297-9. doi: 10.1128/AAC.00147-08. [PubMed: 18426894]. [PubMed Central: PMC2443900].
  • 17. Martinez-Martinez L, Eliecer Cano M, Manuel Rodriguez-Martinez J, Calvo J, Pascual A. Plasmid-mediated quinolone resistance. Expert Rev Anti Infect Ther. 2008;6(5):685-711. doi: 10.1586/14787210.6.5.685. [PubMed: 18847406].
  • 18. Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem? Clin Microbiol Infect. 2008;14(4):295-7. doi: 10.1111/j.1469-0691.2007.01930.x. [PubMed: 18190576].
  • 19. Liu BT, Wang XM, Liao XP, Sun J, Zhu HQ, Chen XY, et al. Plasmid-mediated quinolone resistance determinants oqxAB and aac(6')-Ib-cr and extended-spectrum beta-lactamase gene blaCTX-M-24 co-located on the same plasmid in one Escherichia coli strain from China. J Antimicrob Chemother. 2011;66(7):1638-9. doi: 10.1093/jac/dkr172. [PubMed: 21546384].
  • 20. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother. 2007;51(9):3354-60. doi: 10.1128/AAC.00339-07. [PubMed: 17548499]. [PubMed Central: PMC2043241].
  • 21. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006;12(1):83-8. doi: 10.1038/nm1347. [PubMed: 16369542].
  • 22. Mahon CR, Lehman DC, Manuselis G. Textbook of Diagnostic Microbiology. 5th. Saunders Elsevier; 2014.
  • 23. Cockerill FR, Clinical Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement; M100-S23. Wayne, PA: CLSI; 2013.
  • 24. Dashti AA, Jadaon MM, Abdulsamad AM, Dashti HM. Heat treatment of bacteria: A simple method of DNA extraction for molecular techniques. Kuwait Med J. 2009;41(2):117-22.
  • 25. Winissorn W, Pharm B, Tribuddharat C, Naenna P, Leelarasamee A, Pongpech P. Fluoroquinolone resistance and effect of qnrA integron cassettes in Escherichia coli clinical isolates in a university hospital. J Infect Dis Antimicrob Agents. 2013;30:15-25.
  • 26. Kariuki S, Revathi G, Corkill J, Kiiru J, Mwituria J, Mirza N, et al. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams. J Infect Dev Ctries. 2007;1(3):257-62. [PubMed: 19734602].
  • 27. Johnson JR, Sannes MR, Croy C, Johnston B, Clabots C, Kuskowski MA, et al. Antimicrobial drug-resistant Escherichia coli from humans and poultry products, Minnesota and Wisconsin, 2002-2004. Emerg Infect Dis. 2007;13(6):838-46. doi: 10.3201/eid1306.061576. [PubMed: 17553221]. [PubMed Central: PMC2792839].
  • 28. Warburg G, Hidalgo-Grass C, Partridge SR, Tolmasky ME, Temper V, Moses AE, et al. A carbapenem-resistant Klebsiella pneumoniae epidemic clone in Jerusalem: sequence type 512 carrying a plasmid encoding aac(6')-Ib. J Antimicrob Chemother. 2012;67(4):898-901. doi: 10.1093/jac/dkr552. [PubMed: 22287232].
  • 29. Alheib O, Al Kayali R, Abajy MY. Prevalence of plasmid-mediated quinolone resistance (PMQR) determinants among extended spectrum beta-lactamases (ESBL)-producing isolates of Escherichia coli and klebsiella pneumoniae in Aleppo, Syria. Arch Clin Infect Dis. 2015;10(3). doi: 10.5812/archcid.20631.
  • 30. Cremet L, Caroff N, Dauvergne S, Reynaud A, Lepelletier D, Corvec S. Prevalence of plasmid-mediated quinolone resistance determinants in ESBL Enterobacteriaceae clinical isolates over a 1-year period in a French hospital. Pathol Biol (Paris). 2011;59(3):151-6. doi: 10.1016/j.patbio.2009.04.003. [PubMed: 19481883].
  • 31. Liu BT, Liao XP, Yang SS, Wang XM, Li LL, Sun J, et al. Detection of mutations in the gyrA and parC genes in Escherichia coli isolates carrying plasmid-mediated quinolone resistance genes from diseased food-producing animals. J Med Microbiol. 2012;61(Pt 11):1591-9. doi: 10.1099/jmm.0.043307-0. [PubMed: 22878251].
  • 32. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother. 2007;60(2):394-7. doi: 10.1093/jac/dkm204. [PubMed: 17561500].
  • 33. Dashti AA, Paton R, Amyes SG. Linkage of ciprofloxacin resistance with a single genotypic cluster of Klebsiella pneumoniae. Int J Antimicrob Agents. 2006;27(1):73-6. doi: 10.1016/j.ijantimicag.2005.09.007. [PubMed: 16321509].
  • 34. Pakzad I, Ghafourian S, Taherikalani M, Sadeghifard N, Abtahi H, Rahbar M, et al. qnr Prevalence in Extended Spectrum Beta-lactamases (ESBLs) and None-ESBLs Producing Escherichia coli Isolated from Urinary Tract Infections in Central of Iran. Iran J Basic Med Sci. 2011;14(5):458-64. [PubMed: 23493061]. [PubMed Central: PMC3586849].
  • 35. Iranzad M, Hakemi-Vala M. The Role of parC, parE, and qnrB genes in ciprofloxacin-resistant Escherichia coli isolates from urinary tract infections. Arch Ped infect Dis. 2017;5(3). doi: 10.5812/pedinfect.41504.
  • 36. Firoozeh F, Zibaei M, Soleimani-Asl Y. Detection of plasmid-mediated qnr genes among the quinolone-resistant Escherichia coli isolates in Iran. J Infect Dev Ctries. 2014;8(7):818-22. doi: 10.3855/jidc.3746. [PubMed: 25022290].
  • 37. Pourahmad Jaktaji R, Mohiti E. Study of Mutations in the DNA gyrase gyrA Gene of Escherichia coli. Iran J Pharm Res. 2010;9(1):43-8. [PubMed: 24363705]. [PubMed Central: PMC3869551].
  • 38. Fu Y, Zhang W, Wang H, Zhao S, Chen Y, Meng F, et al. Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli. BMC Infect Dis. 2013;13:8. doi: 10.1186/1471-2334-13-8. [PubMed: 23295059]. [PubMed Central: PMC3576228].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments